A phase I study -: UFT/leucovorin combined with paclitaxel for anthracycline-pretreated advanced breast cancer

被引：0

作者：

Scholz, U ^{[1
]}

Lück, HJ ^{[1
]}

Canzler, U ^{[1
]}

Robner, D ^{[1
]}

Kühnle, H ^{[1
]}

机构：

[1] Med Hsch Hannover, Dept Gynecol Oncol, Frauenklin, D-30659 Hannover, Germany

来源：

ONCOLOGY-NEW YORK | 2000年 / 14卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Taxanes are the most active drugs in the treatment of metastatic breast and ovarian cancer. Weekly therapy with paclitaxel produces notable activity, with remarkably low toxicity. Moreover, combination therapy with paclitaxel and fluorouracil (5-FU) exhibits high activity ill anthracycline-pretreated breast cancer patients: recent studies report response rates of 54% to 69%. UFT plus oral leucovorin constitutes art orally administered compound that provides activity comparable to that of intravenously administered 5-FU plus leucovorin. An open-label phase 1 study was initiated to determine the maximum tolerated dose and dose-limiting toxicities of the combination of weekly paclitaxel and UFT plus leucovorin administered to patients with anthracycline-resistant metastatic breast cancer.

引用

页码：44 / 46

页数：3

共 50 条

[1] Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: A phase II study
Michelotti, A
Gennari, A
Salvadori, B
Tognoni, A
Tibaldi, C
Baldini, E
Conte, PF
[J]. ANNALS OF ONCOLOGY, 1996, 7 (08) : 857 - 860
[2] Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer
Batista, N
Perez-Manga, G
Constenla, M
Ruiz, A
Carabantes, F
Castellanos, J
Barón, MG
Villman, K
Söderberg, M
Ahlgren, J
Casinello, J
Regueiro, P
Murias, A
[J]. BRITISH JOURNAL OF CANCER, 2004, 90 (09) : 1740 - 1746
[3] Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer
N Batista
G Perez-Manga
M Constenla
A Ruiz
F Carabantes
J Castellanos
M Gonzalez Barón
K Villman
M Söderberg
J Ahlgren
J Casinello
P Regueiro
A Murias
[J]. British Journal of Cancer, 2004, 90 : 1740 - 1746
[4] A phase I study of paclitaxel, UFT, and leucovorin
Gojo, I
Tkaczuk, KH
[J]. ONCOLOGY-NEW YORK, 2000, 14 (10): : 76 - 78
[5] Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer
Helgason, H. H.
Kruijtzer, C. M. F.
Huitema, A. D. R.
Marcus, S. G.
Huinink, W. W. ten Bokkel
Schot, M. E.
Schornagel, J. H.
Beijnen, J. H.
Schellens, J. H. M.
[J]. BRITISH JOURNAL OF CANCER, 2006, 95 (07) : 794 - 800
[6] PHASE II STUDY EVALUATING THE ACTIVITY AND TOXICITY OF A BIWEEKLY SCHEDULE OF GEMCITABINE AND PACLITAXEL IN ANTHRACYCLINE-PRETREATED BREAST CANCER
Spinelli, G. P.
Di Seri, M.
Mezi, S.
Oliveti, A.
Tomao, F.
Petricola, F.
Rosati, S.
Ricciardi, S.
Coletta, D.
Romiti, A.
Frati, L.
Tomao, S.
[J]. ANNALS OF ONCOLOGY, 2004, 15 : 24 - 24
[7] Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer
H H Helgason
C M F Kruijtzer
A D R Huitema
S G Marcus
W W ten Bokkel Huinink
M E Schot
J H Schornagel
J H Beijnen
J H M Schellens
[J]. British Journal of Cancer, 2006, 95 : 794 - 800
[8] Vinorelbine and mitomycin C in anthracycline-pretreated patients with advanced breast cancer
Vici, P
DiLauro, L
Carpano, S
Amodio, A
Pignatti, F
Casali, A
Conti, F
Lopez, M
[J]. ONCOLOGY, 1996, 53 (01) : 16 - 18
[9] Docetaxel-cisplatin combined chemotherapy in Japanese patients with anthracycline-pretreated advanced breast cancer
Kariya, S
Ogawa, Y
Nishioka, A
Yoshida, S
[J]. ONCOLOGY REPORTS, 2002, 9 (06) : 1345 - 1349
[10] Phase I/II study of weekly paclitaxel (P), UFT and leucovorin in patients with metastatic breast cancer
Chang, AY
Beith, J
Yeo, W
Boyer, M
Wong, J
Lim, SE
Chan, AT
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 59S - 59S

← 1 2 3 4 5 →